Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 351

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 351
---
 ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. However, failure to obtain approval in one jurisdiction may impact our ability to obtain approval elsewhere. We may not be able to file for marketing approvals and may not receive necessary approvals to commercialize FYARRO and any other product candidates that we may develop in the future, if approved, in any market. A variety of risks associated with marketing FYARRO and any other product candidates we may develop in the future, if approved, internationally could affect our business. We may seek regulatory approval for FYARRO and any future product candidates outside of the United States and, accordingly, we expect that we will be subject to additional risks related to operating in foreign countries if we obtain the necessary approvals, including:

| • |     | differing regulatory requirements in foreign countries; |

| • |     | the potential for so-called parallel importing, which is what happens                                                                                             
 when a local seller, faced with high or higher local prices, opts to import goods from a foreign market with low or lower prices rather than buying them locally; |

| • |     | unexpected changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements; |

| • |     | economic weakness, including inflation, or political instability in particular foreign economies and markets; |

| • |     | compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; |

| • |     | foreign taxes, including withholding of payroll taxes; |

| • |     | foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other 
 obligations incident to doing business in another country;                                                       |

| • |     | difficulties staffing and managing foreign operations; |

| • |     | workforce uncertainty in countries where labor unrest is more common than in the United States; |

| • |     | potential liability under the United States Foreign Corrupt Practices Act (“FCPA”) or comparable 
 foreign regulations;                                                                             |

- 244 -

| • |     | challenges enforcing our contractual and intellectual property rights, especially in those foreign countries that 
 do not respect and protect intellectual property rights to the same extent as the United States;                  |

| • |     | production shortages resulting from any events affecting raw material supply or manufacturing capabilities 
 abroad; and                                                                                                |

| • |     | business interruptions resulting from geo-political actions, including 
 war and terrorism.                                                     |

In addition, recent conflicts in Ukraine and the Middle East have led to, and could continue to lead to, disruption